EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF 2019 NOVEL CORONA VIRUS: A REVIEW

Authors

  • T SAI LAKSHMI SRIKALA Department of Pharmacy Practice, Anurag Pharmacy College, Kodad (M), Suryapet (D), Telangana State, 508 206.

Keywords:

corona virus, ELISA, Monoclonal antibodies (mAbs), Dromedary camels, WHO, Wuhan City

Abstract

Middle East respiratory disorder (MERS), having a high demise rate, which radiate from the Middle East. Novel Corona virus is the causative living being for MERS and (2019-nCoV) was recognized infection by Chinese experts on 7 January. On 31 December 2019, the WHO China Country Office was educated regarding instances of pneumonia of obscure etiologic (obscure reason) identified in Wuhan City, Hubei Province of China. Besides, MERS-CoV first found in dromedary camels and in bats, people. Proof recommends that animals are acting as host for MERS-CoV and transmitting the malady to people. Till the finish of November 2019, an aggregate of 2494 lab instances of Middle East respiratory disorder (MERS), were recorded which incorporates 858 deaths  around the world. At present, no drug or immunization is accessible for Middle East Respiratory Syndrome. As we knew that prevention is better than cure, taking precautions before attacking of the disease is the best way of preventing disease. In this study we discussed about the pathological aspects, treatment strategies and precautions of the disease.

References

1. https://www.who.int/health-topics/coronavirus
2. WHO MERS-CoV Global Summary and Assessment of Risk, Geneva, Switzerland: World Health Organization, 2018.
3. https://www.who.int/emergencies/mers-cov/en/
4. Woo PC, Lau SK, Li KS, Tsang AK, Yuen KY. Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5. Emerging microbes & infections 2012; 1(1): 1-5.
5. Kayali G, Peiris M. A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus. The Lancet Infectious Diseases 2015; 15(5): 495-497.
6. Milne Price S, Miazgowicz KL, Munster VJ. The emergence of the Middle East respiratory syndrome coronavirus. Pathogens and disease 2014; 71(2): 121-136.
7. Watson JT, Hall AJ, Erdman DD, Swerdlow DL, Gerber SI. Unraveling the mysteries of Middle East respiratory syndrome coronavirus. Emerging infectious diseases 2014; 20(6): 1054.
8. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. The Lancet 2015; 386(9997): 995-1007.
9. Chan JFW, Lau SKP, Woo PCY. The emerging novel Middle East respiratory syndrome coronavirus: the “knowns” and “unknowns”. Journal of the Formosan Medical Association 2013; 112(7): 372-381.
10. WHO MERS-CoV Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS currents 2013; 5.
11. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol Biol Rev 2005; 69(4): 635-664.
12. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nature Reviews Microbiology 2009; 7(3): 226-236.
13. Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, Arledge KC. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell research 2013; 23(8): 986.
14. Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proceedings of the National Academy of Sciences 2005; 102(35): 12543-12547.
15. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nature reviews microbiology 2009; 7(6): 439-450.
16. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. Journal of virology 2007; 81(1): 20-29.
17. Lee H, Lei H., Santarsiero BD, Gatuz JL, Cao S, Rice AJ, Johnson ME. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. ACS chemical biology 2015; 10(6): 1456-1465.
18. De Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Advances in virus research 2005; 64: 165-230.
19. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR, Barber GN. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 2000; 13(1): 129-141.
20. Kato H, Takahasi K, Fujita T. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunological reviews 2011; 243(1): 91-98.
21. Anwar MA, Basith S, Choi S. Negative regulatory approaches to the attenuation of Toll-like receptor signaling. Experimental & molecular medicine 2013; 45(2): 11.
22. Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S. Toll-like receptor signal transduction. Experimental & molecular medicine 2007; 39(4): 421-438.
23. Alexopoulou L., Holt A. C., Medzhitov R., Flavell R. A. Recognition of double-stranded RNA and activation of NF-?B by Toll-like receptor 3. Nature 2001; 413(6857): 732-738.
24. Niemeyer D, Zillinger T, Muth, D, Zielecki F, Horvath G, Suliman T, Müller MA. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. Journal of virology 2013; 87(22): 12489-12495.
25. Siu KL, Yeung ML, Kok KH, Yuen KS, Kew C, Lui PY, .Jin DY. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. Journal of virology 2014; 88(9): 4866-4876.
26. Roush S, Fast H, Miner CE, Vins H, Baldy L, McNall R, Vundi V. National Center for Immunization and Respiratory Diseases (NCIRD) Support for Modernization of the Nationally Notifiable Diseases Surveillance System (NNDSS) to Strengthen Public Health Surveillance Infrastructure in the US. In 2019 CSTE Annual Conference. CSTE, 2019.
27. Falzarano D, De Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Benecke AG. Treatment with interferon-?2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques. Nature medicine 2013; 19(10): 1313-1317.
28. Gross AE, Bryson ML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. Annals of Pharmacotherapy 2015; 49(10): 1125-1135.
29. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. The oncologist 2001; 6(1): 34.
30. Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden F. G, Al-Omari A, Merson L. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springer plus 2015; 4(1): 1-8.
31. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Beck C. R. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of infectious diseases 2015; 211(1): 80-90.
32. Winkler AM, Koepsell SA. The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease. Current opinion in hematology 2015; 22(6): 521-526.
33. Modjarrad K. Treatment strategies for Middle East respiratory syndrome coronavirus. Journal of virus eradication 2016; 2(1): 1.
34. Warren T, Jordan R, Lo M, Soloveva V, Ray A, Bannister R, Xu Y. Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides complete therapeutic protection against the development of Ebola virus disease (EVD) in infected non-human primates. In Open Forum Infectious Diseases. Infectious Diseases Society of America 2015; 2(1): LB-2.
35. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Honnold S. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508(7496): 402-405.
36. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johansen LM. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrobial agents and chemotherapy 2014; 58(8): 4885-4893.
37. Chan JFW, Yao Y, Yeung ML., Deng W, Bao L, Jia L, Cai JP. Treatment with lopinavir/ritonavir or interferon-?1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. The Journal of infectious diseases 2015; 212(12): 1904-1913.
38. Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, Tan W. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome corona virus. Journal of virology 2013; 87(24): 13134-13140.
39. Command and Control centre. Middle East Respiratory Syndrome Corona virus; Guidelines for Healthcare Professionals. Ministry of Health 2018; 5(1): 7- 9.

Published

07-10-2021

How to Cite

T SAI LAKSHMI SRIKALA. (2021). EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF 2019 NOVEL CORONA VIRUS: A REVIEW. Innovare Journal of Sciences, 9(6). Retrieved from https://innovareacademics.in/journals/index.php/ijs/article/view/40448

Issue

Section

Review Article(s)